Piper Sandler Starts Coverage on Shattuck Labs with Bullish View
Piper Sandler begins coverage of Shattuck Labs with an Overweight rating and $15 target, highlighting promise of SL-325 ahead of Phase 1 data.
/ 904 items
#Healthcare↓
CalciMedica Tumbles as Safety Concerns Halt Trial of Kidney Injury Drug
CalciMedica discontinues Phase 2 KOURAGE trial for acute kidney injury drug Auxora following safety concerns raised by independent committee monitoring the study.
FDA Approves Repeat Treatment for iDose TR Glaucoma Implant
Glaukos receives FDA approval allowing patients to receive multiple iDose TR treatments for glaucoma management, expanding treatment options.
FDA Halts REGENXBIO Gene Therapy Trials After Brain Tumor Discovery
REGENXBIO shares drop 32% as FDA places clinical hold on two rare disease gene therapies following brain tumor discovery in trial participant.
Altimmune Secures $75M in Direct Stock Offering to Advance Liver Disease Treatment
Altimmune raises $75 million through registered direct offering to fund Phase 3 trial of pemvidutide for MASH treatment and advance its liver disease therapy pipeline.
Cantor Fitzgerald Upgrades Korro Bio on Promise of KRRO-121
Cantor Fitzgerald upgrades Korro Bio to Overweight, citing strong preclinical data and market potential for its lead program KRRO-121.